Marker Therapeutics (MRKR) shares have increased by approximately 114% in the past three months, attributed to strong investor confidence in its lead candidate, MT-601. The Texas-based biotech firm is advancing its phase I APOLLO study on MT-601, a T-cell therapy targeting relapsed or refractory B-cell lymphoma.
Recent data from the APOLLO study, released in August 2025, indicate that about 66% of patients with Non-Hodgkin Lymphoma achieved an objective response, with 50% attaining a complete response. Among patients with Hodgkin Lymphoma, a notable 78% response rate was recorded. Following these promising results, Marker plans to evaluate MT-601 at a higher dose for relapsed diffuse large B cell lymphoma patients and expects additional data in the first half of 2026. Furthermore, the company has secured approximately $10 million in funding to extend its cash runway and support ongoing clinical development.
